

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of claims:

1. – 61. (Cancelled)

62. (Previously presented) A method of treating premature ejaculation in a male consisting of administering to the male

(i) an antidepressant formulated for nasal administration; and

(ii) an antidepressant formulated for local administration to at least a part of the male genitalia;

wherein the antidepressant formulated for nasal administration and the antidepressant formulated for local administration are each independently selected from the group consisting of serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, norepinephrine dopamine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, norepinephrine antagonist/serotonin antagonists, synthetically derived phenylpiperazine antidepressants, antagonists of central L2- α 2 auto and heteroadrenoceptors, and mixtures thereof; and

wherein the concentration of each antidepressant is between 1 to 10% by weight.

63. (Previously presented) A method according to claim 62 wherein the antidepressant is administered prior to or during sexual activity.

64. (Cancelled)

65. (Cancelled)

66. (Previously presented) The method according to claim 62 wherein local administration is directly to the penis.

67. (Cancelled)

68. (Cancelled)

69. (Previously presented) The method according to claim 62, wherein the antidepressant is administered in an amount of between 0.1 and 1000 mg per dose.

70. (Previously presented) The method according to claim 62 wherein a single antidepressant or single combination of antidepressants is administered via the combination of nasal administration and local administration to at least a part of the male genitalia.

71. (Previously presented) The method according to claim 62 wherein two or more different antidepressants or two or more different combinations of antidepressants are administered via the combination of nasal administration and local administration to at least a part of the male genitalia.

72. (Previously presented) The method according to claim 71 wherein the antidepressant combination includes serotonin reuptake inhibitor (SSRIs) and a monoamine oxidase inhibitor.

73. (Previously presented) The method according to claim 62, wherein the antidepressant is massaged into the skin of the male genitalia for about one minute prior to intercourse.

74. (Previously presented) The method according to claim 73 wherein the antidepressant is massaged into the skin of the male genitalia about 30 to 60 minutes prior to intercourse.

75. (Previously presented) The method according to claim 62 wherein the antidepressant is taken nasally within 30 minutes prior to intercourse.

76. (Currently amended) A medicament for the treatment of premature ejaculation, said medicament consisting of

(i) a first formulation comprising an antidepressant formulated for nasal administration; and

(ii) a second formulation comprising an antidepressant formulated for local administration to at least part of the male genitalia;

wherein the antidepressant formulated for nasal administration and the antidepressant formulated for local administration are each independently selected from the group consisting of serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, norepinephrine dopamine reuptake inhibitors, serotonin antagonist and reuptake inhibitors, norepinephrine antagonist/serotonin antagonists, synthetically derived phenylpiperazine antidepressants, antagonists of central L2- α 2 auto and heteroadrenoceptors, and mixtures thereof; and

wherein the concentration of each antidepressant is between 1 to 10% by weight.

77. (Cancelled)

78. (Currently amended) The medicament according to claim 76
wherein said the antidepressant of the first formulation or the second formulation
is a mixture of a serotonin reuptake inhibitor and a monoamine oxidase inhibitor.

79. (Previously presented) The medicament according to claim 77
wherein said serotonin norepinephrine reuptake inhibitor is a bicyclic, tricyclic or
tetracyclic antidepressant.

80. (Currently amended) The medicament according to claim 76
wherein said the antidepressant of the first formulation or the second formulation
is selected from paroxetine, fluoxoetine, sertraline, citalopram hydrobromide,
fluvoxamine, sertraline, nortriptyline hydrochloride, clomipramine hydrochloride,
dothiepin hydrochloride, Imipramine hydrochloride, mianserin hydrochloride,
amitriptyline hydrochloride, phenelzine sulphate, tranylcypromine sulphate,
isocarboxazid, moclobemide, serotonin and/or adrenalin update inhibitors such
as venlafaxine, nefazodone hydrochloride, trazodone, bupropion, mirtazapine,
doxepin hydrochloride, trimipramine or mixtures thereof.

81. (Cancelled)

82. (Previously presented) The medicament according to claim 76,
wherein said antidepressant formulated for local administration to at least part of
the male genitalia further includes an enhancer agent selected from cyclodextrin,
water, a monohydric alcohol, and a polyhydric alcohol.

83. (Currently amended) The medicament according to claim 76,
wherein said antidepressant formulated for local administration to at least part of
the male genitalia second formulation consists of:

about 20 to about 60% water;

about 80% to about 40% alcohols

1 to 10% Hydroxypropyl- β -cyclodextrin (HPBCD); and

an antidepressant; and

wherein said antidepressant and said HPBCD are present in a molar ratio of about 1:0.8 to 1:1.4 respectively.

84. (Cancelled)

85. (Cancelled)